Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 7,745 matching trials from the live ClinicalTrials.gov search.
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
CNF2024 (BIIB021)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
San Diego, California • New York, New York • Houston, Texas
Conditions
Leukemia, Non Hodgkin's Lymphoma, Aplastic Anemia
Interventions
Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 49 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Daratumumab, Questionnaires, Dietary Intervention
Drug · Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Completed No phase listed Observational

The CARRA Registry

NCT01697254
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis, Juvenile Dermatomyositis, Localized Scleroderma, Systemic Sclerosis, Vasculitis, Sarcoid, Fibromyalgia, Primary, Auto-inflammatory Disease, Idiopathic Uveitis Idiopathic
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
9,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML), Multiple Myeloma, Prostate Cancer, Small Cell Lung Cancer, Non-Hodgkins Lymphoma
Interventions
ABBV-075, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Scottsdale, Arizona • Duarte, California • Sacramento, California + 6 more
Conditions
Solid Tumors, Lymphoma
Interventions
KX2-391
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Conditions
Chronic Lymphocytic Leukemia
Interventions
lenalidomide, Rituximab, Fludarabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Bethesda, Maryland + 2 more
Conditions
Leukemia, Lymphoma
Interventions
lumiliximab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
Interventions
Nivolumab, Ipilimumab, Lirilumab, Daratumumab, Pomalidomide, Dexamethasone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
32
States / cities
Clovis, California • Los Angeles, California • Aurora, Colorado + 16 more
Conditions
Fatigue, Multiple Myeloma
Interventions
armodafinil, Placebo
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Anaheim, California • Newport Beach, California • West Hollywood, California
Conditions
B-cell Lymphoma, Non Hodgkin Lymphoma, Multiple Myeloma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Indolent Lymphoma, B Cells--Tumors
Interventions
STRO-001
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 17 more
Conditions
Ewing's Sarcoma, Leukemia, Lymphoma, Brain Tumors, Rhabdomyosarcoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 40 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Primary Amyloidosis
Interventions
NEOD001
Drug
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 3 more
Conditions
B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Chronic Lymphocytic Leukemia, Transformed Lymphoma
Interventions
Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
Drug
Lead sponsor
John Lister
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Active, not recruiting Phase 2 Interventional Results available

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

NCT04938232
Conditions
Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
everolimus, lenalidomide, laboratory biomarker analysis, polymorphism analysis, immunohistochemistry staining method, microarray analysis, fluorescence in situ hybridization
Drug · Other · Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions
Ibrutinib, MEDI4736
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 8 more
Conditions
Hodgkin Lymphoma
Interventions
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor
Radiation · Drug
Lead sponsor
University College, London
Other
Eligibility
16 Years to 69 Years
Enrollment
1,042 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
3
States / cities
Stanford, California • Miami, Florida • New York, New York
Conditions
Leukemia, Lymphoma
Interventions
Total Lymphoid Irradiation, Fludarabine, Cyclophosphamide, Thiotepa, Melphalan, HPC,A Infusion, TC-NK Infusion, G-CSF, Mesna, CliniMACS, Mycophenolate mofetil
Radiation · Drug · Biological + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
Interventions
Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
Biological · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Hematological Malignancies
Interventions
Tacrolimus and Thymoglobulin
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Lymphoma
Interventions
rituximab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Lenalidomide, nab-paclitaxel
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York